

**Washington State Pharmacy and Therapeutics Committee**

**Drug Utilization Review Board**

**Date: February 19, 2020**

**Time: 9 a.m. to 12 p.m.**

**Port of Seattle “International A” Conference Room**

**Seattle-Tacoma International Airport**

**17801 International Blvd., Seattle, WA 98158**

9 a.m.	Welcome & Introductions  <b>Pharmacy &amp; Therapeutics Committee Convenes</b>	Ginni Buccola, Committee Chair
9:05 a.m.	Newer Diabetes- draft report Incretin Mimetics/Enhancers - Amylin Analogs - DPP4 inhibitors - GLP1 Agonists - DPP4 Inhibitor/SGLT2 Inhibitor Combinations - DPP4 Inhibitor/TZD Combinations - GLP1 Agonist/Insulin Combinations - SGLT2 Inhibitors <ul style="list-style-type: none"><li>• Stakeholder input*</li><li>• P&amp;T Motion</li></ul>	Rosalie Kelly, DERP Umang Patel, Magellan
10:25 a.m.	<b>Pharmacy &amp; Therapeutics Committee Adjourns</b> <b>Drug Utilization Review (DUR) Board Convenes</b>	Ginni Buccola, Committee Chair
10:25 a.m.	Insulin and related agents - Rapid Acting - Short Acting - Pre-Mixed - Intermediate Acting - Long Acting <ul style="list-style-type: none"><li>• Stakeholder input*</li><li>• Motion- Insulin and related agents</li><li>• Motion- Incretin Mimetics/Enhancers</li></ul>	Umang Patel, Magellan
10:45 a.m.	Thiazolidinediones <ul style="list-style-type: none"><li>• Stakeholder input*</li><li>• Motion</li></ul>	Umang Patel, Magellan
10:50 a.m.	Pancreatic Enzymes <ul style="list-style-type: none"><li>• Stakeholder input*</li><li>• Motion</li></ul>	Umang Patel, Magellan
10:55 a.m.	Growth Hormone & Growth Factors - Growth Hormone Releasing Hormones (GHRH) - Growth Hormones <ul style="list-style-type: none"><li>• Stakeholder input*</li><li>• Motion</li></ul>	Umang Patel, Magellan
11:20 a.m.	Ulcerative Colitis Agents - Inflammatory Bowel Agents <ul style="list-style-type: none"><li>• Stakeholder input*</li></ul>	Umang Patel, Magellan

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> <li>• Motion</li> </ul>	
11:30 a.m.	Cystic Fibrosis Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:40 a.m.	Inhaled Antibiotics <ul style="list-style-type: none"> <li>- Aminoglycosides</li> <li>- Monobactams</li> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:45 a.m.	Anticoagulants: Factor Xa and Thrombin Inhibitors <ul style="list-style-type: none"> <li>Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:50 a.m.	Topical Antiparasitics: Scabicides and Pediculicides <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:55 a.m.	Lipotropics <ul style="list-style-type: none"> <li>- PCSK-9 Inhibitors</li> <li>- Microsomal Triglyceride Transfer Protein Inhibitor (MTP)</li> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
12 p.m.	<b>Drug Utilization Review Board Adjourns</b>	Ginni Buccola, Committee Chair

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.